Taufon eye drops 40 mg/ml bottle 10 ml

Pharmacodynamics. Taufon refers to amino acid preparations that stimulate reparative and regenerative processes in diseases of the retina of the eye of a dystrophic nature, traumatic eye injuries, pathological processes that are accompanied by a sharp violation of the metabolism of these tissues. As a sulfur-containing compound, the drug contributes to the normalization of cell membrane functions, optimization of energy and metabolic processes, maintenance of the constancy of the electrolyte composition of the cytoplasm of cells, inhibition of synaptic transmission (neurotransmitter role).

Pharmacokinetics. When instilled, Taufon penetrates the tissues of the eye, where it exerts its specific effect. When used in therapeutic doses, the drug is practically not absorbed into the systemic bloodstream.

Dystrophic lesions of the cornea and retina, including hereditary tapetoretinal degeneration; senile, diabetic, traumatic and radiation cataracts; as a means of stimulating reparative processes in corneal injuries; as an additional agent in the treatment of open-angle glaucoma.

Taufon is prescribed for adults.

For the treatment of cataracts, 2-3 drops are prescribed 2-4 times a day. The course of treatment is 3 months. The course is repeated with an interval of 1 month.

In case of an accident, apply 2-3 drops 2-4 times a day for 1 month.

For the treatment of tapetoretinal degeneration and other degenerative diseases of the retina, penetrating corneal injuries, the drug is administered under the conjunctiva at 0.3 ml of a 4% solution once a day for 10 days. The course of treatment is repeated after 6-8 months.

In open-angle glaucoma, Taufon is instilled 2-3 drops into the conjunctival sac 2 times a day 20-30 minutes before the use of timolol. The course of treatment is determined individually.

Hypersensitivity to the drug and its components.

The drug is usually well tolerated. In some patients, allergic reactions, conjunctival hyperemia, itching, burning and stinging in the eyes may develop.

In open-angle glaucoma, the drug is used in combination with timolol 20-30 minutes before instillation of timolol.

Use during pregnancy or breastfeeding. The efficacy and safety of use during pregnancy or breastfeeding have not been studied.

Children: The efficacy and safety of use in children have not been studied.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms has not been studied.

When used simultaneously with timolol eye drops, a potentiation of the decrease in intraocular and arterial pressure is observed.

Cases of overdose have not been described.

In a place protected from light at a temperature of 5-25 °C.